Although these drugs indeed show clinical benefits to HER2-positive breast cancer patients, acquired resistance is still developed eventually and remains a hurdle to be overcome (Nahta et al., 2009; Rexer and Arteaga, 2012; Pernas and Tolaney, 2019). Here, ERBB2 is linked to breast cancer.